It is becoming increasingly clear that improving mRNA properties is crucial for accelerating mRNA therapeutics that typically require high and repeated dosing, as well as a localized therapeutic effect and precise activity.
That is why RIBOPRO has been dedicated to developing a range of complementary technologies over the past few years that enhance mRNA therapeutics with a high level of fidelity, low immunogenicity, and reduced passive off-target effects.
Click here to read more about “Leveraging the Power of mRNA: How Biotech Scale-up, RiboPro, Is Revolutionizing Therapeutic Development“
